NASDAQ: RNACCartesian Therapeutics Inc Stock
$10.50-0.07 (-0.66%)
Updated Apr 17, 2025
RNAC Price
$10.50
Fair Value Price
-$4.63
Market Cap
$272.02M
52 Week Low
$8.85
52 Week High
$41.87
P/E
-2.34x
P/B
-39.99x
P/S
7.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$38.91M
Earnings
-$77.42M
Gross Margin
100%
Operating Margin
-198.23%
Profit Margin
-199%
Debt to Equity
-64.96
Operating Cash Flow
-$24M
Beta
1.29
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RNAC Overview
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RNAC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RNAC
Ranked#163 of 463
Ranked#163 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important RNAC news, forecast changes, insider trades & much more!
RNAC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNAC ($10.50) is overvalued by 327.01% relative to our estimate of its Fair Value price of -$4.63 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNAC ($10.50) is not significantly undervalued (327.01%) relative to our estimate of its Fair Value price of -$4.63 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNAC due diligence checks available for Premium users.
Valuation
RNAC fair value
Fair Value of RNAC stock based on Discounted Cash Flow (DCF)
Price
$10.50
Fair Value
-$4.63
Undervalued by
327.01%
RNAC ($10.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNAC ($10.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RNAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.34x
Industry
-177.72x
Market
27.98x
RNAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-39.99x
Industry
4.05x
RNAC's financial health
Profit margin
Revenue
-$759.0k
Net Income
-$10.3M
Profit Margin
1,350.9%
RNAC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RNAC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$435.0M
Liabilities
$441.8M
Debt to equity
-64.96
RNAC's short-term assets ($216.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNAC's long-term liabilities ($418.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.0M
Investing
-$354.0k
Financing
$783.0k
RNAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNAC vs Biotech Stocks
Cartesian Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.